1CITTERIO F, SCATA M C,BORZI M T, et al. C2 singlepoint sampling to evaluate cyclosporine exposure in long-term renal transplant recipients[J]. Transplant Proc, 2001,33 (7-8):3133-3136.
2LEVY G,BURRA P,CAVALLARI A, et al. Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2 hr post-dose levels (C2)[J ].Transplantation, 2002,73(6): 953-959.
3CANTAROVICH M,ELSTEIN E,de VARENNES B, et al.Clinical benefit of neoral dose monitoring with cyclosporine 2-hr post-dose levels compared with trough levels in stable heart transplant patients [J]. Transplantation, 1999, 68 (12): 1839-1842.
4JOHNSTON A,DAVID O J,COONEY G F. Pharmacokinetic validation of neoral absorption profiling[J]. Transplant Proc,2000,32(suppl 3A): 53s-56s.
5BELITSKY P. Neoral use in the renal transplant recipient[J].Transplant Proc,2000,32(suppl 3A):10-19.
6CANTAROVICH M, BESNER J G, BARKUN J S, et al.Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy[J]. Clin Transplant, 1998,12(3) :243-249.
7WARRENS A N, WATERS J B, SALAMA A D, et al.Improving the therapeutic monitoring of cyclosporin A[J]. Clin Transplant, 1999,13(2): 193.
8PRIMMETT D R, LEVINE M, KOVARIK J M, et al.Cyclosporine monitoring in patients with renal transplants:two-or three-point methods that estimate area under the curve are superior to trough levels in predicting drug exposure[J].The Drug Monit, 1998,20(3): 276.
